Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Ancient meditation practices find new life in modern religious communities across America - 2Ukraine Now Using Drone Boats To Attack Russian Riverine Targets
- 3Vietnam rethinks its flood strategy as climate change drives storms and devastation
- 4The Most Notable Design Brands of the 21st Hundred years
- 5Arctic sea ice hits lowest winter level as unprecedented heat hits smashes records all over Earth
- Vote in favor of your Number one Kind of Gems
- L.A.'s most famous midcentury home, the Stahl House, is on the market for the 1st time, at $11K per square foot: See inside
- The Conclusive Manual for Spending plan Travel: Opening Undertakings on a Tight budget
- Moscow accuses Berlin of stifling the opposition
- 6 Exceptionally Appraised Summer Travel Objections
- Effectiveness Uncovered: A Survey of \Smoothing out Your Errands\ Efficiency Application
- Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
- A Time of Careful Eating: Individual Tests in Nourishment
- Paraplegic engineer becomes the first wheelchair user to blast into space
